

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

DISCLOSEABLE TRANSACTION IN RELATION TO CAPITAL CONTRIBUTION IN AND ACQUISITION OF 100% EQUITY INTEREST IN FENGSHUO BIO MEDICAL TECH AND 51% EQUITY INTEREST IN GUANGDONG KELV BIO MEDICAL TECH COMPANY LIMITED AND CAPITAL CONTRIBUTION TO OBTAIN 28% EQUITY INTEREST IN FENGYUAN HUAKE BIO TECH

Reference is made to the announcement dated 23 November 2015 (“**2015 Announcement**”) of Common Splendor International Health Industry Group Limited (the “**Company**”). Unless the context otherwise states, capitalised terms used in this announcement have the same meanings as those defined in the 2015 Announcement.

PROFIT GUARANTEE

Pursuant to the Agreement, Mr. Zhao, the Vendor and the Target Company No. 1 have undertaken to the Purchaser and Fengshuo Bio Medical Tech that the 2017 Actual Profit, being the audited net profit after taxation of the Target Company No. 1 for the year ending 31 December 2017, prepared in accordance with the PRC accounting standards will not be less than the Guarantee Profit (i.e. RMB38,000,000).

If the Guarantee Profit is not achieved, Mr. Zhao and the Vendor have undertaken to transfer a percentage of the equity interest of the Target Company No. 1 (“X”) to the Purchaser, Fengshuo Bio Medical Tech or a company designated by the Purchaser at no further consideration, based on the following formula:

$$X = 28\% \times (\text{RMB}38,000,000 / 2017 \text{ Actual Profit} - 1) \times 100\%$$

For the purpose of the above price adjustment calculation, 2017 Actual Profit shall be taken as RMB38,000,000 where it is more than RMB38,000,000 and taken as RMB11,320,000 where it is less than RMB11,320,000.

POSSIBLE COMPENSATION

While the audited accounts of the Target Company No. 1 for the year ended 31 December 2017 is still in the process of being prepared in accordance with the PRC accounting standards, based on information currently available to the Company, including management accounts of the Target Company No. 1, it is expected that the Target Company No. 1 will not be able to meet the Guarantee Profit. According to the Agreement, Mr. Zhao and the Vendor shall transfer X to the Purchase according to the agreed formula stated above. The Company will further consider and negotiate, based on the audited accounts of the Target Company and, where applicable, take any appropriate actions for the compensation for any non-fulfillment of the Guarantee Profit. Further announcement(s) will be made by the Company as and when appropriate.

By order of the Board
**Common Splendor International Health
Industry Group Limited**
Cheung Wai Kuen
Chairman

Hong Kong, 28 March 2018

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Lin Jiang and Mr. Hou Kaiwen as non-executive Directors; and Mr. Mai Yang Guang, Mr. Wong Yiu Kit, Ernest and Mr. Lam Chi Wing as independent non-executive Directors.